Dr. Nicola Normanno (National Cancer Institute Pascale Foundation, Naples Italy) explains the clinical need to assess homologous recombination deficiency (HRD) in tumor types beyond ovarian cancer and discusses why comprehensive genomic profiling (CGP) inclusive of HRD is advantageous in identifying actionable mutations with therapeutic interventions. Finally, Dr. Normanno describes the advantages of in-house testing and why he believes it is an exciting time for the Oncology field.

Watch this video to learn more about how CGP and HRD can improve total patient care.

#HRD #CGP #precisionmedicine #oncology #diagnostics #BRCA #cancer #illumina

Subscribe to the Illumina video channel http://www.youtube.com/subscription_c...

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.

View customer spotlight videos
   • Illumina Customer Testimonials  

View Illumina webinars
   • Webinars  

View Illumina support videos
   • Illumina Support  

Facebook:   / illuminainc  
LinkedIn:   / illumina  
Instagram:   / illuminainc  
Twitter:   / illumina